Article
LSD liberated me from the prison I had built for myself
Four years since that trip, I’m no longer prescribed antidepressants.
Article
Four years since that trip, I’m no longer prescribed antidepressants.
Article
We spoke with an experienced psychiatrist about how exactly prescribing ketamine for depression works.
Article
Clashes between SSDP and New College administrators represent growing confusion about handling harm reduction on campuses
Article
A team of researchers bathed octopuses in MDMA. Here’s what they learned.
Article
A conversation between two (white) activists to further the dialogue around inclusivity in the field of psychedelic research and culture.
Article
Like the vast majority of psychonauts, I didn’t use a chemical reagent to verify I was taking LSD, even though I had been active in harm reduction work for three years prior and was aware of testing kits.
Article
Before I met Adam I didn’t really know anyone with OCD. It was just an abstract concept to me. Like most people, I had the image of the stereotypical germaphobe who obsessively scrubs their hands in a futile attempt at washing the thousands of bacteria away.
Article
Rhana Hashemi is the site coordinator for drug and alcohol programs and services for Oakland Unified School District. But, to her students, she is just “the drug lady.”
Article
Vincent Horn of Meditate.io talks about psychedelics and meditation.
Article
Think of a glass of water: under normal circumstances you might think ‘I drink water when I’m thirsty’. But when consuming a psychedelic substance you might think ’water is the essence of life’.
Article
We need new drugs. The opioid epidemic gripping the United States has brought into public awareness a problem that has bedeviled the world of medical science for decades: is it possible to have a truly powerful painkiller that is not addictive?
Article
Why researchers like Alan Kooi Davis — the newest addition to the Johns Hopkins psychedelic research team — decide to devote their careers to studying psychedelics.
Psymposia is a research and media 501(c)(3) nonprofit that offers critical perspectives on drugs, politics, and culture.
We rely on audience support to keep our work independent and focused on the public interest. You can sustain Psymposia by becoming a member, which includes exclusive content and perks.